LyondellBasell Industries N.V.
LYBLyondellBasell Industries N.V.'s price has outrun its earnings. +24.8% in a year against EPS −156.4% — the market is paying now for delivery later.
The sharpest disagreement: the price moved +24.8% in a year while annual EPS moved −156.4% — the difference is re-rating, and re-rating has to be repaid with earnings.
The price is in a confirmed uptrend (10 weeks in) while the P/E sits at the 92nd percentile of its own 4-year range. Underneath, the last four quarters read improving — profit +600.0% year on year, and 207% of the last 3 years' profit arrived as cash. What settles it: whether earnings grow into a price that has already moved.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
LyondellBasell Industries N.V. trades at $64.9, in a confirmed uptrend and 10 weeks into that stage. That is +6.1% against its own 200-day average. It sits at 58% of a 52-week range of $43 to $80. On relative strength it has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week.
Today the stock is in a confirmed uptrend — week 10 of stage 2. At $64.9 it trades +6.1% versus its 200-day average and sits at 58% of its 52-week range ($43–$80).
Against the market, two honest reads. Cumulative: over the last 10.2 years the stock moved −15% while the S&P 500 moved +255% — behind the index over the full window. Recent form: on a trailing-13-week view the stock has been ahead for 1 straight week — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
Valuation P/E is the price of $1 of annual profit: how many dollars the market pays for each dollar the company earns in a year.
LyondellBasell Industries N.V. trades at 64.5× P/E, at the pricey end of its own range (92nd percentile). Its long-run median P/E is 13.5×, measured across 3.8 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 64.5× is at the pricey end of its own range (92nd percentile), against a long-run median of 13.5× measured over 3.8 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
🚨 Why the multiple sits where it does: over the past year annual EPS moved −156.4% against a +24.8% price move — the price outran earnings, pushing the multiple UP its own range.
The price move, decomposed: over 3y, of the −13.4%/yr price move, ~−59.9%/yr came from earnings growth and ~+46.5 pp from the multiple (expanding). The split is the honest approximate (price return minus earnings growth); it makes the rally itself visible instead of hiding it behind the percentile.
Put together: the multiple is full against its own past, so the story rests on the earnings line underneath it, not the multiple.
Stage: Deteriorating Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
LyondellBasell Industries N.V. reads as deteriorating on its fundamental arc. Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −9.4% latest against −9.4% at its 12-quarter best), ROCE slipping at -1.1%. The read is built from 12 quarters across 4 curves, on full evidence.
🚨 Why it matters: falling curves mean every cheap-looking ratio below needs a discount for direction.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | −9.7% | −15.8% | — | — |
| Stock price | +24.8% | −13.4% | −6.8% | −1.7% |
4-Factor Sector Score
44.6/100 — rank 20 of 29 in Specialty Chemicals · 71% evidence confidence
LyondellBasell Industries N.V. scores 44.6 out of 100 against the 29 companies it is compared with in Specialty Chemicals, ranking 20. Price leads the evidence: RS versus the benchmark is 4.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
The four contributions add to the total exactly: 12.8 + 6.3 + 8.5 + 17 = 44.6. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
LyondellBasell Industries N.V. reported $7.2 B of revenue in the Mar 26 quarter, −6.2% year on year. Over 4 years it has compounded at −10.1% a year. The last full year, FY25, came in at $30.1 B. The last four reported quarters add to $29.7 B.
FY25 revenue came in at $30.1 B (−9.7% on the year), capping 4 years at −10.1% compound. The latest quarter (Mar 26) printed $7.2 B, −6.2% year on year.
Pace check: the last four quarters averaged −9.3% growth against the decade's −10.1% — the current year is running in line with its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew −9.4% over the last 4 quarters against −13.0%/yr over the last 8 — accelerating.
Operating margin Operating margin is what is left of every $100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
LyondellBasell Industries N.V.'s operating margin is 3.3% in the Mar 26 quarter, +1.9 percentage points against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −1.4% to 14.7%. The current quarter sits inside that band.
The latest quarter's operating margin is 3.3%, +1.9 pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −1.4%–14.7%.
Why the margin moved: operating margin went +1.9 pp year on year while gross margin went +2.5 pp — the gain came mostly from the gross line: input costs and pricing.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
LyondellBasell Industries N.V. earned $0.1 B of net profit in the Mar 26 quarter, +600.0% year on year. The full FY25 year was a loss of $0.8 B. That is 1.9% of the quarter's revenue. The same quarter a year earlier earned $0.0 B. 3 of the last 12 reported quarters were loss-making.
Mar 26 profit was $0.1 B, +600.0% year on year. On the full year, FY25 printed $−0.8 B (−154.9%).
Why profit moved: revenue contributed −6.2% and the margin +1.9 pp — the quarter was revenue-led, with the margin roughly flat.
Pace comparison, last four quarters: profit +94.7% vs revenue −9.3%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra dollar of revenue drops more to the bottom line.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 207% of LyondellBasell Industries N.V.'s reported profit arrived as operating cash — the cash follows the profit. In FY25 that was $2.3 B of operating cash against $−0.8 B of profit. After $1.9 B of capital spending, $0.4 B was left as free cash.
FY25: operating cash of $2.3 B against reported profit of $−0.8 B, leaving free cash of $0.4 B after $1.9 B of capital spending. Across the last 3 fiscal years the conversion rate is 207% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why: conversion is measured cleanly, but the working-capital day-counts behind it sit below what we hold — the move is shown without inventing its driver.
Router verdict: the visible cash user is investment — the next section checks what the spending is buying.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
LyondellBasell Industries N.V. does not report the debtor, inventory and payable day-counts a cash cycle is built from, so this section reads the investment side instead. Capital spending ran $5.0 B over the last 3 years. Averaged over those years that is 5.5% of FY25 revenue a year.
Working-capital day-counts are not in our numbers for this stock, so this section reads the investment side — where the cash is being put to work.
On the investment side: capital spending of $5.0 B over the last 3 fiscal years.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
Return on equity Return on equity (ROE) is the profit the business earns on its shareholders’ money. With the full capital-employed split not in our numbers, ROE is the cleanest long ladder we can draw here.
LyondellBasell Industries N.V. earns a ROE of −8% in FY25. Return on invested capital clears the cost of that capital by +5.5 percentage points, so growth here adds value rather than only size. The wiring behind it is −2.6% net margin on 0.89× asset turns.
FY25 ROE is −8%.
Why the return is what it is — the wiring (FY25): −2.6% net margin × 0.89× asset turns × 3.33× balance-sheet leverage ≈ −7.7% on equity. Margin does its share; leverage is a meaningful part of the equation.
The capstone test — ROIC − WACC: 10.4% − 4.9% = a +5.5 pp spread. The 4.9% is an estimate of this company's own cost of capital — read the sign and the size of the spread, not the decimals. A spread this wide means every dollar reinvested creates more than a dollar of value — the engine compounds.
Dividend A dividend is cash paid out per share. Dividend per share is the declared amount for the period; the trailing twelve-month total is the four most recent quarters added together.
LyondellBasell Industries N.V. paid $4.80 per share over the last four reported quarters, down 48.5% on a year ago. The most recent declaration was $0.69 for Mar 26. Against the current price of $64.9 that is a trailing yield of 7.40%, measured on dividends already paid rather than on a forecast.
LyondellBasell Industries N.V. paid $4.80 per share across the last four reported quarters, most recently $0.69 for Mar 26. That is down 48.5% against the same quarter a year earlier. Against the current price of $64.9 the trailing twelve months work out to 7.40% — trailing dividends measured against today's price, not a forward estimate.
Debt Debt-to-equity says how much of the business is funded by borrowings. Low is the safe corner; the trend matters as much as the level.
LyondellBasell Industries N.V. carries total debt of $14.3 B against shareholder equity of $10.2 B as of Mar 26, a debt-to-equity of 1.40. On the annual view that ratio went from 0.07 in FY21 to 1.40 in FY25. Read the returns elsewhere on this page with that leverage in mind.
Mar 26: total debt of $14.3 B against shareholder equity of $10.2 B — a debt-to-equity of 1.40. On the annual view, debt-to-equity went from 0.07 (FY21) to 1.40 (FY25). Read the returns on this page with that leverage in mind.
Ownership There is no quarter-by-quarter holder register to read here, so we read the crowd through short interest — the slice of tradable shares currently sold short, positioned for a fall.
5.4% of LyondellBasell Industries N.V.'s tradable float is currently sold short — some money is positioned against it. At typical trading volumes those positions would take about 3.4 days to buy back. There is no quarter-by-quarter holder register to read for this filer, so the crowd is read through short interest instead.
The latest reading: 5.4% of the float is sold short, and at typical trading volumes it would take about 3.4 days to buy those positions back. Some money is positioned against it. This is a single point-in-time reading — we do not yet hold its history, so we show no trend chart.
Why it sits there: who is doing the shorting, and why, does not travel with the number — the level is shown without inventing its story.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
LyondellBasell Industries N.V.: the Z-score reads 2.04. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits in the grey band between the two. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 2.04 sits in the grey band — neither clearly safe nor clearly distressed.
The safety line in one sentence: the Z-score reads 2.04.
| Company | Score | Price stage | Growth & earnings/35 | Capital efficiency/25 | Valuation/20 | Relative strength/20 |
|---|---|---|---|---|---|---|
| 1NewMarket CorporationNEU | 62.9/100Thin evidence · provisional58% evidence | BREAKING OUT | 16.6/35 Revenue — · PAT — · OPM change -1.4 pp 45% evidence | 15.7/25 ROCE 5.5% · OPM 21.4% 76% evidence | 11.4/20 P/E 17× · PEG — 15% evidence | 19.2/20 RS sector 11.2% · RS bench 12.1% · 1Y 9.2%11 of 12 weeks ahead 100% evidence |
| Exact sum: 16.6 + 15.7 + 11.4 + 19.2 = 62.9 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 2Sociedad Química y Minera de Chile S.A.SQM | 62.4/100Mixed-positive evidence81% evidence | ASLEEP | 29.0/35 Revenue 18.3% · PAT 48.4% · OPM change 17.4 pp 83% evidence | 15.3/25 ROCE 6.3% · OPM 41% 76% evidence | 13.7/20 P/E 28.4× · PEG 0.81 65% evidence | 4.4/20 RS sector -8.8% · RS bench -9.3% · 1Y 58%0 of 12 weeks ahead 100% evidence |
| Exact sum: 29 + 15.3 + 13.7 + 4.4 = 62.4 · Decision use: Acceleration candidate, not a confirmed leader: earnings are strong but sector-relative strength is -8.8% and the one-year return is 58%. Do not upgrade until sector-relative strength is above zero and another reported period confirms growth. | ||||||
| 3Sensient Technologies CorporationSXT | 61.3/100Thin evidence · provisional58% evidence | BREAKING OUT | 20.1/35 Revenue — · PAT — · OPM change 1.7 pp 45% evidence | 12.1/25 ROCE 3.8% · OPM 15.3% 76% evidence | 9.7/20 P/E 33.2× · PEG — 15% evidence | 19.4/20 RS sector 13.6% · RS bench 13.9% · 1Y 24.6%9 of 12 weeks ahead 100% evidence |
| Exact sum: 20.1 + 12.1 + 9.7 + 19.4 = 61.3 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 4Avient CorporationAVNT | 58.0/100Mixed-positive evidence64% evidence | BREAKING OUT | 20.6/35 Revenue 1.3% · PAT 56.9% · OPM change 11.2 pp 62% evidence | 8.9/25 ROCE 1.9% · OPM 11.3% 76% evidence | 10.9/20 P/E 21.1× · PEG — 15% evidence | 17.6/20 RS sector 6.4% · RS bench 6.3% · 1Y 16.5%7 of 12 weeks ahead 100% evidence |
| Exact sum: 20.6 + 8.9 + 10.9 + 17.6 = 58 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 5International Flavors & Fragrances Inc.IFF | 56.6/100Mixed-positive evidence64% evidence | BREAKING OUT | 21.0/35 Revenue -5.6% · PAT — · OPM change 41.8 pp 62% evidence | 6.9/25 ROCE 1.2% · OPM 10% 76% evidence | 10.6/20 P/E 22.2× · PEG — 15% evidence | 18.1/20 RS sector 7.7% · RS bench 7.8% · 1Y 32.9%6 of 12 weeks ahead 100% evidence |
| Exact sum: 21 + 6.9 + 10.6 + 18.1 = 56.6 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 6PPG Industries, Inc.PPG | 55.0/100Mixed-positive evidence85% evidence | ASLEEP | 18.6/35 Revenue 5% · PAT 52.2% · OPM change -1.2 pp 95% evidence | 15.9/25 ROCE 12.6% · OPM 14% 76% evidence | 15.8/20 P/E 17.2× · PEG 0.29 65% evidence | 4.7/20 RS sector -10.5% · RS bench -10.4% · 1Y -4.1%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.6 + 15.9 + 15.8 + 4.7 = 55 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 7Quaker Chemical CorporationKWR | 52.8/100Thin evidence · provisional58% evidence | FADING | 21.5/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 8.0/25 ROCE 1.7% · OPM 7% 76% evidence | 10.5/20 P/E 28.3× · PEG — 15% evidence | 12.8/20 RS sector -1.1% · RS bench -0.7% · 1Y 10.9%9 of 12 weeks ahead 100% evidence |
| Exact sum: 21.5 + 8 + 10.5 + 12.8 = 52.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 8Ashland Inc.ASH | 51.7/100Thin evidence · provisional58% evidence | FADING | 18.9/35 Revenue — · PAT — · OPM change -2.5 pp 45% evidence | 6.7/25 ROCE 1% · OPM 8.1% 76% evidence | 8.8/20 P/E 57.8× · PEG — 15% evidence | 17.3/20 RS sector 10.5% · RS bench 10.7% · 1Y 41.7%11 of 12 weeks ahead 100% evidence |
| Exact sum: 18.9 + 6.7 + 8.8 + 17.3 = 51.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 9Balchem CorporationBCPC | 51.5/100Thin evidence · provisional58% evidence | FADING | 18.4/35 Revenue — · PAT — · OPM change 0.1 pp 45% evidence | 13.9/25 ROCE 3.8% · OPM 20.5% 76% evidence | 9.8/20 P/E 33.2× · PEG — 15% evidence | 9.4/20 RS sector -4.7% · RS bench -4.5% · 1Y 7.1%4 of 12 weeks ahead 100% evidence |
| Exact sum: 18.4 + 13.9 + 9.8 + 9.4 = 51.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 10WD-40 CompanyWDFC | 50.7/100Thin evidence · provisional58% evidence | ASLEEP | 21.1/35 Revenue — · PAT — · OPM change 0.4 pp 45% evidence | 16.7/25 ROCE 10.8% · OPM 16.3% 76% evidence | 10.2/20 P/E 30.4× · PEG — 15% evidence | 2.7/20 RS sector -17.3% · RS bench -17.1% · 1Y -9.8%6 of 12 weeks ahead 100% evidence |
| Exact sum: 21.1 + 16.7 + 10.2 + 2.7 = 50.7 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 11Ingevity CorporationNGVT | 50.6/100Thin evidence · provisional58% evidence | ASLEEP | 22.0/35 Revenue — · PAT — · OPM change 2 pp 45% evidence | 12.0/25 ROCE 4.5% · OPM 26.6% 76% evidence | 8.9/20 P/E 53.7× · PEG — 15% evidence | 7.7/20 RS sector -3.2% · RS bench -3.5% · 1Y 21.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 22 + 12 + 8.9 + 7.7 = 50.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 12Linde plcLIN | 50.3/100Mixed-positive evidence85% evidence | ASLEEP | 19.3/35 Revenue 6.6% · PAT 7.7% · OPM change -0.2 pp 95% evidence | 19.1/25 ROCE 13.8% · OPM 28.1% 76% evidence | 5.9/20 P/E 33.1× · PEG 3.28 65% evidence | 6.0/20 RS sector -8.9% · RS bench -8.8% · 1Y -3.5%0 of 12 weeks ahead 100% evidence |
| Exact sum: 19.3 + 19.1 + 5.9 + 6 = 50.3 · Decision use: Strong business, demanding price: keep it on the quality list, but require either earnings upgrades or valuation compression. | ||||||
| 13The Sherwin-Williams CompanySHW | 49.1/100Mixed-negative evidence85% evidence | ASLEEP | 20.7/35 Revenue 5.8% · PAT 15.5% · OPM change 0.7 pp 95% evidence | 15.9/25 ROCE 7.1% · OPM 18.1% 76% evidence | 5.0/20 P/E 31.7× · PEG 4.15 65% evidence | 7.5/20 RS sector -10.7% · RS bench -10.2% · 1Y -7.3%4 of 12 weeks ahead 100% evidence |
| Exact sum: 20.7 + 15.9 + 5 + 7.5 = 49.1 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 14Axalta Coating Systems Ltd.AXTA | 49.0/100Thin evidence · provisional58% evidence | ASLEEP | 15.5/35 Revenue — · PAT — · OPM change -2.3 pp 45% evidence | 11.5/25 ROCE 2.8% · OPM 11.6% 76% evidence | 10.8/20 P/E 21.1× · PEG — 15% evidence | 11.2/20 RS sector -1.2% · RS bench -0.8% · 1Y 10%8 of 12 weeks ahead 100% evidence |
| Exact sum: 15.5 + 11.5 + 10.8 + 11.2 = 49 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 15H.B. Fuller CompanyFUL | 48.7/100Mixed-negative evidence85% evidence | ASLEEP | 21.2/35 Revenue -0.6% · PAT 80.6% · OPM change 1.2 pp 95% evidence | 10.8/25 ROCE 2.6% · OPM 12.3% 76% evidence | 15.1/20 P/E 19× · PEG 0.5 65% evidence | 1.6/20 RS sector -20.6% · RS bench -20.2% · 1Y -16.4%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.2 + 10.8 + 15.1 + 1.6 = 48.7 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 16Ecolab Inc.ECL | 47.8/100Mixed-negative evidence85% evidence | FADING | 15.4/35 Revenue 7.1% · PAT -1% · OPM change -0.4 pp 95% evidence | 13.1/25 ROCE 3.5% · OPM 17.2% 76% evidence | 9.9/20 P/E 37.4× · PEG 1.4 65% evidence | 9.4/20 RS sector -6.3% · RS bench -5.9% · 1Y 3.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 15.4 + 13.1 + 9.9 + 9.4 = 47.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 17Eastman Chemical CompanyEMN | 47.5/100Thin evidence · provisional58% evidence | ASLEEP | 18.5/35 Revenue — · PAT — · OPM change -4.6 pp 45% evidence | 12.8/25 ROCE 4.8% · OPM 8.6% 76% evidence | 11.2/20 P/E 17.4× · PEG — 15% evidence | 5.0/20 RS sector -11.8% · RS bench -11.8% · 1Y -0.1%0 of 12 weeks ahead 100% evidence |
| Exact sum: 18.5 + 12.8 + 11.2 + 5 = 47.5 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 18RPM International Inc.RPM | 47.4/100Thin evidence · provisional58% evidence | ASLEEP | 18.3/35 Revenue — · PAT — · OPM change 0.8 pp 45% evidence | 12.2/25 ROCE 4.8% · OPM 5% 76% evidence | 11.0/20 P/E 20.5× · PEG — 15% evidence | 5.9/20 RS sector -13.5% · RS bench -13% · 1Y -18.5%2 of 12 weeks ahead 100% evidence |
| Exact sum: 18.3 + 12.2 + 11 + 5.9 = 47.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 19Cabot CorporationCBT | 44.7/100Mixed-negative evidence81% evidence | ASLEEP | 8.7/35 Revenue -8.5% · PAT -31.2% · OPM change -3 pp 83% evidence | 12.7/25 ROCE 4.5% · OPM 14.3% 76% evidence | 16.5/20 P/E 14.2× · PEG 0.18 65% evidence | 6.8/20 RS sector -3.8% · RS bench -3.7% · 1Y 1.2%4 of 12 weeks ahead 100% evidence |
| Exact sum: 8.7 + 12.7 + 16.5 + 6.8 = 44.7 · Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity. | ||||||
| 20LyondellBasell Industries N.V.this pageLYB | 44.6/100Mixed-negative evidence71% evidence | TURNING | 12.8/35 Revenue -9.4% · PAT -164.8% · OPM change 1.8 pp 83% evidence | 6.3/25 ROCE 0.9% · OPM 3.3% 76% evidence | 8.5/20 P/E 76.1× · PEG — 15% evidence | 17.0/20 RS sector 4.8% · RS bench 4.2% · 1Y 24.8%1 of 12 weeks ahead 100% evidence |
| Exact sum: 12.8 + 6.3 + 8.5 + 17 = 44.6 · Decision use: Price leads the evidence: RS versus the benchmark is 4.2%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 21Calumet, Inc.CLMT | 42.3/100Mixed-negative evidence64% evidence | BREAKING OUT | 8.9/35 Revenue -0.1% · PAT — · OPM change -11.7 pp 62% evidence | 3.1/25 ROCE -9.1% · OPM -16.6% 76% evidence | 10.3/20 P/E 30.3× · PEG — 15% evidence | 20.0/20 RS sector 81.6% · RS bench 79.8% · 1Y 213.4%11 of 12 weeks ahead 100% evidence |
| Exact sum: 8.9 + 3.1 + 10.3 + 20 = 42.3 · Decision use: Price leads the evidence: RS versus the benchmark is 79.8%, but earnings trajectory is weak. Wait for revenue and profit confirmation. | ||||||
| 22Element Solutions IncESI | 40.1/100Thin evidence · provisional58% evidence | ASLEEP | 17.6/35 Revenue — · PAT — · OPM change 0.3 pp 45% evidence | 10.4/25 ROCE 2.3% · OPM 13.3% 76% evidence | 8.7/20 P/E 64.5× · PEG — 15% evidence | 3.4/20 RS sector -9.5% · RS bench -9.9% · 1Y 21.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 17.6 + 10.4 + 8.7 + 3.4 = 40.1 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 23DuPont de Nemours, Inc.DD | 39.5/100Mixed-negative evidence81% evidence | ASLEEP | 21.4/35 Revenue 4% · PAT 40.7% · OPM change 5.2 pp 83% evidence | 7.2/25 ROCE 0.7% · OPM 11.1% 76% evidence | 4.7/20 P/E 45.4× · PEG 4.12 65% evidence | 6.2/20 RS sector -19.9% · RS bench -19.1% · 1Y -45.6%0 of 12 weeks ahead 100% evidence |
| Exact sum: 21.4 + 7.2 + 4.7 + 6.2 = 39.5 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 24Perimeter Solutions, Inc.PRM | 38.8/100Thin evidence · provisional58% evidence | ASLEEP | 10.1/35 Revenue — · PAT — · OPM change -50 pp 45% evidence | 7.4/25 ROCE -7.6% · OPM 58% 76% evidence | 9.0/20 P/E 53.3× · PEG — 15% evidence | 12.3/20 RS sector 5.1% · RS bench 5.3% · 1Y 45.7%5 of 12 weeks ahead 100% evidence |
| Exact sum: 10.1 + 7.4 + 9 + 12.3 = 38.8 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 25Albemarle CorporationALB | 38.0/100Thin evidence · provisional53% evidence | ASLEEP | 20.0/35 Revenue — · PAT — · OPM change 14.5 pp 32% evidence | 8.8/25 ROCE 1.6% · OPM 16.3% 76% evidence | 9.1/20 P/E 47.9× · PEG — 15% evidence | 0.1/20 RS sector -29% · RS bench -29.3% · 1Y 33.8%0 of 12 weeks ahead 100% evidence |
| Exact sum: 20 + 8.8 + 9.1 + 0.1 = 38 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 26Hawkins, Inc.HWKN | 37.6/100Thin evidence · provisional58% evidence | BASING | 14.9/35 Revenue — · PAT — · OPM change -1.2 pp 45% evidence | 11.9/25 ROCE 4.4% · OPM 8.8% 76% evidence | 9.4/20 P/E 41.9× · PEG — 15% evidence | 1.4/20 RS sector -21.8% · RS bench -21.4% · 1Y -29.2%0 of 12 weeks ahead 100% evidence |
| Exact sum: 14.9 + 11.9 + 9.4 + 1.4 = 37.6 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
| 27Air Products and Chemicals, Inc.APD | 35.8/100Mixed-negative evidence85% evidence | BREAKING OUT | 6.3/35 Revenue 4.5% · PAT -99.8% · OPM change -92.5 pp 95% evidence | 5.7/25 ROCE -5.8% · OPM -66.3% 76% evidence | 12.9/20 P/E 30.7× · PEG 0.82 65% evidence | 10.9/20 RS sector -3.8% · RS bench -3.7% · 1Y -1.1%1 of 12 weeks ahead 100% evidence |
| Exact sum: 6.3 + 5.7 + 12.9 + 10.9 = 35.8 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 28Westlake CorporationWLK | 27.0/100Adverse evidence64% evidence | BASING | 9.8/35 Revenue -8.6% · PAT -473.1% · OPM change -5.4 pp 62% evidence | 4.8/25 ROCE -1% · OPM -6.5% 76% evidence | 9.6/20 P/E 33.6× · PEG — 15% evidence | 2.8/20 RS sector -21.9% · RS bench -22.2% · 1Y -14.9%0 of 12 weeks ahead 100% evidence |
| Exact sum: 9.8 + 4.8 + 9.6 + 2.8 = 27 · Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction. | ||||||
| 29Solstice Advanced Materials, Inc.SOLS | 45.4/100Thin evidence · provisional36% evidence | ASLEEP | 12.5/35 Revenue — · PAT — · OPM change -4.5 pp 39% evidence | 14.3/25 ROCE 9.6% · OPM 16.5% 76% evidence | 8.6/20 P/E 67.2× · PEG — 15% evidence | 10.0/20 RS sector — · RS bench — · 1Y —0 of 12 weeks ahead 0% evidence |
| Exact sum: 12.5 + 14.3 + 8.6 + 10 = 45.4 · Decision use: Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral. | ||||||
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step curve the sector itself is placed on — basing, turning, breaking out, leader, fading, asleep — read from how many weeks running it has led S&P 500 and whether that lead is widening or shrinking. It describes where the PRICE stands, not the earnings trajectory and not a recommendation, and it is left blank for a company whose weekly history is too short or too stale to read.
Frequently asked questions
What is LyondellBasell Industries N.V.'s stock price today?
LyondellBasell Industries N.V. trades at $64.9, +24.8% over the past year. The company is valued at $21.0 B. The stock sits at 58% of its 52-week range of $43–$80, +6.1% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 10 weeks in. — as of 17 September 2026.
What were LyondellBasell Industries N.V.'s latest quarterly results?
LyondellBasell Industries N.V. reported revenue of $7.2 B and net profit of $0.1 B for the Mar 26 quarter. Revenue fell 6.2% and profit rose 600.0% year on year. Earnings per share were $0.38. The operating margin was 3.3%, 1.9 pp higher than a year earlier. — as of 17 September 2026.
What is LyondellBasell Industries N.V.'s revenue?
LyondellBasell Industries N.V. reported revenue of $7.2 B in the Mar 26 quarter, −6.2% year on year. For the full FY25 fiscal year, revenue was $30.1 B (−9.7%). Over the last 4 years revenue compounded at −10.1% a year. — as of 17 September 2026.
What is LyondellBasell Industries N.V.'s profit?
LyondellBasell Industries N.V. earned $0.1 B of net profit in the Mar 26 quarter, +600.0% year on year. Full-year FY25 profit was $−0.8 B. The operating margin ran 3.3% in the latest quarter. — as of 17 September 2026.
What is LyondellBasell Industries N.V.'s market cap?
LyondellBasell Industries N.V.'s market capitalisation is $21.0 B at a stock price of $64.9. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 17 September 2026.
What is LyondellBasell Industries N.V.'s P/E ratio?
LyondellBasell Industries N.V. trades at a P/E of 64.5×, at the 92nd percentile of its own 4-year range, against a long-run median of 13.5×. This is a comparison with the stock's own history, not a value call — as of 17 September 2026.
Does LyondellBasell Industries N.V. pay a dividend?
Yes — LyondellBasell Industries N.V. declared $0.69 per share for Mar 26, and $4.80 per share across the last four reported quarters. The latest quarter is down 48.5% on the same quarter a year earlier. — as of 17 September 2026.
What is LyondellBasell Industries N.V.'s dividend per share?
LyondellBasell Industries N.V.'s most recently declared dividend is $0.69 per share for Mar 26, giving $4.80 per share over the trailing twelve months. Each figure is the amount declared for that quarter as reported, added across four quarters for the trailing total. — as of 17 September 2026.
What is LyondellBasell Industries N.V.'s dividend yield?
LyondellBasell Industries N.V.'s trailing dividend yield is 7.40%: $4.80 declared per share across the last four reported quarters, against a share price of $64.9. Each quarter’s figure is the amount declared for that quarter as reported, added across four quarters and divided by the latest close. — as of 17 September 2026.
Is LyondellBasell Industries N.V. overvalued?
On its own history, LyondellBasell Industries N.V. looks expensive: its P/E of 64.5× sits at the 92nd percentile of its 4-year range (long-run median 13.5×). That is a percentile read against the stock's own past, not a price opinion or a direction call. — as of 17 September 2026.
Is LyondellBasell Industries N.V. growing?
Yes — LyondellBasell Industries N.V. is growing: latest-quarter revenue −6.2% year on year, profit +600.0%, and the margin +1.9 pp at 3.3%. The earnings engine currently reads: improving — as of 17 September 2026.
How is LyondellBasell Industries N.V. performing?
LyondellBasell Industries N.V. is in a confirmed uptrend, 10 weeks in. Its latest quarter's revenue fell 6.2% and profit rose 600.0% year on year. Against the S&P 500 it has been ahead on a trailing-13-week view for 1 week. This describes what the data did, not a rating. — as of 17 September 2026.
What stage is LyondellBasell Industries N.V. in?
Deteriorating — revenue, profit and EPS growth are shrinking (revenue growth −9.4% latest against −9.4% at its 12-quarter best), ROCE slipping at -1.1%. The read comes from the last 12 quarters of growth (revenue growth −9.4% latest, profit growth −164.4% latest, eps growth −177.2% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 17 September 2026.
Is LyondellBasell Industries N.V. in an uptrend?
Yes — the price is in a confirmed uptrend (week 10 of stage 2), trading +6.1% versus its 200-day average and at 58% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 17 September 2026.
Is LyondellBasell Industries N.V. beating the market?
On recent form, yes — LyondellBasell Industries N.V. has been ahead of the S&P 500 on a trailing-13-week view for 1 straight week, the same metric the week-by-week ribbon on this page draws. Separately, on the cumulative view: over the last 10.2 years the stock moved −15% against the S&P 500's +255% — behind the index over the full window. — as of 17 September 2026.
Will LyondellBasell Industries N.V.'s stock price go up?
This page publishes no price forecast for LyondellBasell Industries N.V. What it measures instead: the stock price is $64.9, the price is in a confirmed uptrend 10 weeks in. Its P/E of 64.5× sits at the 92nd percentile of its own 4-year range. — as of 17 September 2026.
Is the market betting against LyondellBasell Industries N.V.?
Somewhat — short interest is 5.4% of LyondellBasell Industries N.V.'s tradable float, about 3.4 days to cover at typical volumes. A moderate reading: some money is positioned against it. With no quarter-by-quarter holder register here, short interest is the cleanest crowd read we hold — as of 17 September 2026.
Does LyondellBasell Industries N.V. have too much debt?
It carries real leverage — LyondellBasell Industries N.V.'s debt-to-equity is 1.33. A year-by-year borrowings ladder is not in our numbers for this stock, so the latest reading is the cleanest hold. Read the returns on this page with that leverage in mind — as of 17 September 2026.
What is LyondellBasell Industries N.V.'s capex?
LyondellBasell Industries N.V. spent $5.0 B on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY25 alone that was $1.9 B. — as of 17 September 2026.
What is LyondellBasell Industries N.V.'s cash flow?
LyondellBasell Industries N.V. generated $2.3 B of operating cash flow in FY25 and $0.4 B of free cash flow after $1.9 B of capital spending. Reported profit that year was $−0.8 B, so operating cash ran ahead of profit. — as of 17 September 2026.
Is LyondellBasell Industries N.V.'s profit real cash?
Yes — over the last 3 fiscal years, 207% of LyondellBasell Industries N.V.'s reported profit arrived as operating cash. Though the latest year ran at -286% — the trend is the thing to watch. In FY25, operating cash was $2.3 B against reported profit of $−0.8 B. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 17 September 2026.
How financially safe is LyondellBasell Industries N.V.?
On the balance sheet, the Z-score reads 2.04 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That is in the grey band — neither clearly safe nor clearly distressed. — as of 17 September 2026.
Where is LyondellBasell Industries N.V. in its business cycle?
LyondellBasell Industries N.V.'s FY25 operating margin was −1.4%, against a 5-year band of −1.4%–14.7%: the low end of its own band, which is where recoveries start when they come. The latest quarter ran 3.3%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 17 September 2026.
What could break the LyondellBasell Industries N.V. story?
The sharpest disagreement: the price moved +24.8% in a year while annual EPS moved −156.4% — the difference is re-rating, and re-rating has to be repaid with earnings. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 17 September 2026.
Is LyondellBasell Industries N.V. a stock worth studying right now?
This is not investment advice. The machine read: LyondellBasell Industries N.V.'s price has outrun its earnings. +24.8% in a year against EPS −156.4% — the market is paying now for delivery later. The sharpest open question: whether earnings grow into a price that has already moved. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 17 September 2026.
Not SEBI Registered !! Not Investment advice !!